Pulsus Development
Early-stage strategy, before clinical development is set.
Pulsus Development is our specialist unit for early-stage assets. It answers one question: should this asset progress, and if so, how?
We work with pharma and biotech teams before the clinical plan is fixed. With a network of scientific partners, we turn preclinical data into a decision you can act on.
What we do
- Review preclinical evidence and study design.
- Test the mechanism of action and whether it will translate to patients.
- Identify workable clinical hypotheses and target populations.
- Define early development pathways.
- Set preclinical findings against clinical and regulatory reality.
The Translational Bridge
Our Translational Bridge links early science to later use. We place each preclinical finding against three tests:
- Is there a plausible clinical development strategy?
- Is it feasible with regulators?
- Would it matter in real-world treatment?
How it differs from the rest of Pulsus
The main consultancy works across clinical development and after approval. Its question is: how do we get the most value from this asset?
Pulsus Development works earlier. Its question is: should this asset go forward at all?
Where it helps
- Asset evaluation and prioritisation.
- Business development and licensing decisions.
- Positioning new mechanisms.
Getting these decisions right early lowers risk later and supports more confident investment.
Tell us what you’re working on
Initial discussions are confidential and without obligation. Send a short note and we will reply.
